



RNS: RELEASE

2 June 2026

ImmuPharma PLC
("ImmuPharma" or the "Company")

Notice of AGM & Annual Report & Accounts

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting ("AGM") has today been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2025 has also been posted to shareholders today.

These documents will be available shortly, in electronic form, for download on the Company's website www.immupharma.co.uk.

ImmuPharma's AGM will be held on Thursday 25th June 2026 @ 11:00am (BST) at the offices of Broadfield Law UK LLP, One Bartholomew Close, London EC1A 7BL.

Ends

ImmuPharma PLC (www.immupharma.co.uk)

Tim McCarthy, Chief Executive Officer and Chairman

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

+44 (0) 203 368 8974

Stanford Capital Partners (Joint Broker)

Patrick Claridge, Bob Pountney

+44 (0) 203 650 3650

SI Capital (Joint Broker)

Nick Emerson

+44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

The lead program, P140, is a unique non-immunosuppressive peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases. Kapiglucagon is being developed for the treatment of type 1 diabetes.

For additional information about ImmuPharma please visit www.immupharma.co.uk.

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.